PAR has more risk in many ways - they’re actually trialing still at an earlier stage for their drug , has not been phase 3 trials as have been for RAC’s development drug .
Much as I want PAR also to do well - and for asx listed biotech and biomedical stocks to be recognised more ! , and valued appropriately !
* RAC has nearer endpoints , and enormous past and recent proof data .
**Bisantrene is a phase 3 asset , a number of past phase 3 trials and was fully approved previously for AML. ( never had approval removed - bisantrene’s effectiveness is known and it saves lives of patients otherwise with no hope of making it . Literally all treatment options exhausted . Several patients alive still today because of bisantrene .)
Base case :
*Efficacy is really without doubt for bisantrene with AML , and really also for breast cancer — from past phase 3 trials in each.
The market isn’t seeing what RAC hold.
Ann: Race Strategic Update March 2021, page-380
-
- There are more pages in this discussion • 140 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |